Individual response to drug therapy: Bases and study approaches

Revista de Investigacion Clinica

Volumn 64, Issue 4, 2012, Pages 364-376

  Leoń Cachón, Rafael Baltazar Reyes ^a   Ascacio Martínez, Jorge Ángel ^a   Barrera Saldaña, Hugo Alberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Drugs; Human genome; Individualized medicine

Indexed keywords

CYTOCHROME P450; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; RECOMBINANT PROTEIN;

BIOTECHNOLOGY; DISEASE COURSE; DNA MICROARRAY; DRUG ABSORPTION; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG TRANSPORT; FOOD AND DRUG ADMINISTRATION; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDEL MUTATION; LIVER MICROSOME; PROTEIN EXPRESSION; REVIEW; RNA SPLICING; TANDEM REPEAT;

BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; DRUG LABELING; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMAN GENOME PROJECT; HUMANS; INDIVIDUALIZED MEDICINE; INTESTINAL ABSORPTION; MICROSOMES, LIVER; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 84869780279     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526. (Pubitemid 350116943)
2. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001; 482: 11-19. (Pubitemid 32787077)
3. Motulsky AG. Drug reactions enzymes and biochemical genetics. J Am Med Assoc 1957; 165: 835-7.
4. Motulsky AG, Qi M. Pharmacogenetics, pharmacogenomics and ecogenetics. J Zhejiang Univ Sci B 2006; 7: 169-70.
5. Marshall A. Genset-Abbott deal heralds pharmacogenomics era. Nat Biotechnol 1997; 15: 829-30.
6. Joseph T, Dipiro RLT, Gary C Yee, Gary R Matzke, Barbara G, Wells L, Posey M. Pharmacogenetics. In: Pharmacotherapy A pathophysiologic approach. Posey LM (ed.); New York: The McGraw-Hill; 2008, p. 2559.
7. O'Shaughnessy KM. HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol 2006; 61: 783-6. (Pubitemid 43794811)
8. Lander ES, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
9. Venter JC, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
10. Science, U.S.D.o.E.O.o. Genomics and Its Impact on Science and Society:The Human Genome Project and Beyond. Human Genome Program A Primer, 12 (2008).
11. Collins FS, et al. New goals for the U.S. Human Genome Project: 1998-2003. Science 1998; 282: 682-9. (Pubitemid 28489375)
12. Pang AW, et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol 2010; 11: R52.
13. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-73.
14. Lewin B. Genes IX. Sudbury, Massachusetts: Jones And Bartlett Publishers; 2008.
15. Madsen BE, Villesen P, Wiuf C. Short tandem repeats and genetic variation. Methods Mol Biol 2010; 628: 297-306.
16. Hall IP. Pharmacogenetics, pharmacogenomics and airway disease. Respir Res2002; 3: 10.
17. Redon R, et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-54. (Pubitemid 44809057)
18. Li J, et al. Whole genome distribution and ethnic differentiation of copy number variation in Caucasian and Asian populations. PLoS One 2009; 4: e7958.
19. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746-50. (Pubitemid 36044701)
20. Paine MF, et al. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006; 34: 880-6.
21. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005; 207: 52-6.
22. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006; 25: 1679-91.
23. Reyes-Hernandez OD, et al. A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacology 2008; 81: 97-103. (Pubitemid 351182683)
24. Qin J, Jones RC, Ramakrishnan R. Studying copy number variations using a nanofluidic platform. Nucleic Acids Res 2008; 36: e116.
25. Casner PR. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. J Clin Pharmacol 2005; 45: 1230-5. (Pubitemid 41513045)
26. Gamazon ER, Huang RS, Dolan ME, Cox NJ. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol 2011; 12: R46.
27. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-37. (Pubitemid 43261982)
28. Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Land B Biol Sci 2005; 360: 1563-70.
29. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 2004; 4: 1385-98. (Pubitemid 39242880)
30. Sakurai A, et al. Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 2007; 46: 7678-93. (Pubitemid 47016053)
31. Putnam WS, Woo JM, Huang Y, Benet LZ. Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol 2005; 45: 411-21. (Pubitemid 40490414)
32. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004; 60: 97-102. (Pubitemid 38626438)
33. Sekine T, Cha SH, Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch 2000; 440: 337-50. (Pubitemid 30445708)
34. Niemi M, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-78. (Pubitemid 40824960)
35. Thompson MD, Siminovitch KA, Cole DE. G protein-coupled receptor pharmacogenetics. Methods Mol Biol 2008; 448: 139-85.
36. Limdi NA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83: 312-21.
37. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-05. (Pubitemid 28193431)
38. Pirmohamed M, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19. (Pubitemid 38869995)
39. Nelson MR, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009; 9: 23-33.
40. Donato MT, O'connor JE. Monography. 2009.
41. Administration, U.S.F.a.D. Pharmacogenomics and its role in drug safety. FDA Drug Safety Newsletter 2008; 1: 24-6.
42. Invitrogen. P450-3A4 BACULOSOMES® Reagents, rHuman.
43. Castell JV, Gómez-Lechón MJ. Drug Metabolism and Carcinogen Activation Studies with Human Genetically Engineered Cells. In: José VC, María José GL (eds.). In vitro Methods in Pharmaceutical Research. San Diego: Academic Press; 1996, p. 432-49.
44. Landsiedel R, Fabian E, Tralau T, Luch A. Chemical toxicity testing in vitro using cytochrome P450-expressing cell lines, such as human CYP1B1. Nat Protocols 2011; 6: 677-88.
45. Hong H, Goodsaid F, Shi L, Tong W. Molecular biomarkers: a US FDA effort. Biomark Med 2010; 4: 215-25.
46. Ekins S, Vanden-Branden M, Ring BJ, Wrighton SA. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997; 7: 165-79. (Pubitemid 27290630)
47. Pelkonen O, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82: 667-715.
48. Masimirembwa CM, Thompson R, Andersson TB. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 2001; 4: 245-63. (Pubitemid 32433637)
49. Lee SJ, et al. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos 2009; 37: 2262-9.
50. Preissner S, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010; 38: D237-D243.
51. McGinnity DF, Riley RJ. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Trans 2001; 29: 135-9. (Pubitemid 32587492)
52. Turpeinen M, et al. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 2009; 37: 1017-24.
53. Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 2009; 37: 1025-34.
54. Kudzma EC, Carey ET. Pharmacogenomics: Personalizing Drug Therapy. American Journal of Nursing 2009; 109: 50-7.
55. Dumond JB, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87: 735-42.
56. Dumaual C, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 2007; 8: 293-305. (Pubitemid 46477741)
57. Tejedor D, et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005; 51: 1137-44. (Pubitemid 43079390)
58. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009; 59: 42-55.
59. Mega JL, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
60. Barrera-Saldaña HA. Nanofarmalab: Un DNAChip para la predicción de la respuesta a tratamientos farmacológicos (FONCI-CYT Fondo: C0002, Convocatoria: C0002-2008-01, Solicitud: 000000000095773, Vitagénesis S.A. (Monterrey, NL), Progenika Biopharma S.A. (Derio, España), Innopsys S.A.(Carbone, Francia) y Laboratorios Silanes S.A. (México, DF). Octubre 2009-Junio 2013).
61. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 2011; 78: 243-57.
62. U.S. Department of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies. Clinical Pharmacology 2011.
63. Mallal S, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79. (Pubitemid 351214284)